Genetic variation in the apolipoprotein E (APOE) gene is associated with Alzheimer's disease (AD) and risk factors for cardiovascular disease (CVD). DNA methylation at APOE has been linked to altered cognition and AD. It is unclear if epigenetic marks could be used for predicting future disease. We assessed blood-based DNA methylation at 13 CpGs in the APOE gene in 5828 participants from the Generation Scotland (GS) cohort. Using linear regression, we examined the relationship between APOE methylation, cognition, cholesterol, and the risks for AD and CVD. DNA methylation at two CpGs was associated with the ratio of total-to-HDL cholesterol, but not with cognition, or the risks of AD or CVD. APOE methylation could be involved in the levels of blood cholesterol, but there is no evidence for the utility of APOE methylation as a biomarker for predicting AD or CVD.
gene is associated with dementia [14, 15, 16, 17] with neuritic amyloid plaque burden [18] , and with cognitive ability [19] .
Associations have been suggested between epigenetic mechanisms and risk factors for cardiovascular disease [20, 21, 22, 23] . Whereas a recent systematic review identified 34 candidate-gene studies on methylation in CVD [4] , few have explored modifications in APOE, and there have been some conflicting results: while Karlsson et al. [15] found no evidence for differences in APOE methylation in blood between patients with CVD and healthy controls, Ji et al. [24] reported APOE hypermethylation in the blood of patients with coronary heart disease compared to controls.
To help clarify this role of APOE, we utilize data from Generation Scotland, a large populationbased cohort, the size of which is several times greater than samples in previous studies, providing a robust analysis of APOE methylation and cognitive and vascular health. We characterise blood-based methylation in the promoter region, 2 nd and 3 rd exons and introns, and 4 th exon of the APOE gene, and explore links between APOE methylation and a variety of markers of cognitive function, AD, vascular health, and CVD. Due to the importance of developing new clinical biomarkers for health outcomes before the onset of disease, we restrict our sample to ages between 30 and 65 years.
Methods

The sample
Generation Scotland (GS; [25, 26] ) is a family-based cohort of over 22,000 individuals from Scotland (aged 18-99 years) that were genotyped and extensively phenotyped during the 4 baseline assessment between the years 2006 and 2011. Blood-based genome-wide DNAmethylation were generated in 9551 individuals as part of the sub-study Stratifying Resilience and Depression Longitudinally (STRADL; [27] ).
Methylation and APOE measurements
DNA methylation in peripheral blood samples was profiled in two sets (Set 1: n = 5,087 in 2017 and Set 2: n = 4,450 in 2019), using the Illumina HumanMethylationEPIC BeadChip as described previously [28] . Briefly, low quality samples, probes with low detection rates, and participants for which the predicted sex did not match the recorded sex were excluded (Supp.
Methods 1).
We removed related participants from Set 1 using a genetically determined relationship cutoff of >0.05 (GCTA GREML; [29] ) to reduce the potential influence of shared genetics on the findings. The participants in Set 2 were unrelated to each other and to those in Set 1. We restricted the analysis to CpGs located on chromosome 19 between 45,409,039 -45,412,650bp, which corresponded to the region encompassing the APOE-gene (UCSC GRCh37/hg19 genome build). To restrict the age of our sample, we removed participants younger than 30 years and older than 65 years. After combining the two sets, our final sample consisted of a total of 13 CpGs in 5,828 participants (Supp. Figure 1) .
APOE-haplotype status was determined using Taqman technology at the Clinical Research
Facility, Western General Hospital, Edinburgh. Based on the identity of the nucleotides at SNPpositions rs429358 and rs7412, participants with the ε3/ε3-haplotype were classified as ε3carriers, participants with the ε2/ε2-and ε2/ε3-haplotypes were classified as ε2-carriers, and participants with the ε3/ε4-and ε4/ε4-haplotypes were classified as ε4-carriers. The 126 participants (2.2%) with the ε2/ε4-genotype were not included in analyses in which carrierstatus was implemented as a variable.
Characterisation of APOE methylation
We examined the methylation status of 13 CpGs in the APOE gene ( Figure 1A) . Twelve CpGs exhibited similar methylation levels to those previously described (Supp . Table 1 ; [15, 16, 22] ), whereas one of them (cg20051876, which is unique to the Illumine EPIC array) had not been reported before. Based on the Illumina-annotated locations of the CpGs on the chromosome, their relative distances to each other, and their methylation levels, the CpGs were classified into three groups: hypermethylated (each site > 50% mean methylation) and lying in the promoter region (region 1: cg20051876, cg14123992, cg04406254), hypomethylated (each site < 50% mean methylation) and lying in the region encompassing the first two exons and introns (region 2: cg26190885, cg12049787, cg08955609, cg18768621, cg19514613, cg06750524), and hypermethylated and lying in the 4 th exon (region 3: cg16471933, cg05501958, cg18799241, cg21879725). 
Cognitive variables
Approximations for the risk of AD and of CVD
Only three participants reported having AD, and 203 participants (3.5%) reported having CVD.
We therefore created approximate measures of risk that were based on reports by participants about these illnesses for close relatives (parents, siblings, and grandparents). For both AD and CVD, each relative was assigned either 0 or 1 (0: absence of the disorder, 1:
presence of the disorder) based on the report of the participant. To derive each risk measure, we calculated the weighted sums of family records for each participant as follows:
The choice of weights used for a given family member was based on kinship/relatedness between that relative and the participant. The participants that self-reported as having AD or CVD were excluded from the models that included the risk of AD or the risk of CVD as predictor variables, respectively. Due to a low number of relatives with AD and a consequential skew in the distribution of AD-risk, AD-risk was transformed into a categorical variable AD-class (low risk: no close relatives with AD, n = 4854; high risk: at least one close relative with AD, n = 974). For cholesterol levels, the total-to-HDL ratio was used.
Covariates
For alcohol consumption, we did not include participants that have quit drinking (n = 373) or whose answers relating to recent alcohol consumption according to their own assessment did not correspond to their usual drinking pattern (n = 1557). Information on smoking was processed as described previously [30] ; we did not include participants that have quit smoking (n = 673). The sample sizes for the fully-adjusted models (see below) thus depended on the included covariates with missing values. Smoking was assessed in pack years and alcohol consumption in units per week. Activity levels were recorded in minutes per week; two different versions of the questionnaire were used in the study, with each participant completing only one of them. We therefore combined the two versions so that the responses by all participants were on the same scale (Supp. Methods 2).
Statistical analysis
For all numerical variables, outliers -defined as scores beyond four interquartile ranges from the median -were excluded. For each analysis, linear mixed models were built. For each CpG (outcome), two models were run: (1) a basic-adjusted model containing the primary predictor variables as defined in the hypothesis and (2) 
The predictor-specific covariates used in the fully-adjusted model varied according to the predictor variable of the model and, whenever possible, corresponded with previous studies [15, 22] . Both the basic-and the fully-adjusted model included as covariates the batch in which the samples of a given participant were processed on the array (fitted as a random effect on the intercept) and the estimated proportions of CD8+-and CD4+-T-cells, natural killer cells, B cells, monocytes, and granulocytes. Cell composition correction controls for the fact that DNA methylation patterns can be confounded by the heterogeneity of cells in the tissue used for analysis [31] .
The threshold for statistical significance was Bonferroni-corrected for each CpG. All continuous variables (except the variable age when used as a predictor) were transformed to have a mean of 0 and a standard deviation of 1. When the predictor was a categorical variable, analysis of variance was performed, comparing the model of interest with the same model excluding the predictor variable.
All statistical analyses were performed in R.
Results
Sample characteristics
Among the 5828 participants, 3399 (58.3%) were female and 2429 (41.7%) were male. The age range was 30-65 years and the mean age was 52.7 years ( Table 1) . APOE genotype frequencies were comparable to those described previously for the British population (Table   1 ; [10, 32] ). Correlations between DNA methylation levels in blood (this study) and brain tissue (publicly available datasets) for the 13 CpGs in this study ranged from -0.30 to 0.51 for the whole brain (IMAGE-CpG: https://han-lab.org/methylation/default/imageCpG, [ 
Association between CpGs
The correlations in methylation for all pairwise combinations between the 13 CpGs ranged from -0.49 to 0.78, with a mean absolute correlation of 0.32 (Figure 1B) . After correcting for multiple comparisons, 68/78 correlations were statistically significant at p<6.4x10 -4 (=0.05/78), with 38 (60%) positive, and 30 (40%) negative. CpGs within a region tended to be methylated to a similar extent: all significant correlations among CpGs within region 1 (3/3, 100%) and within region 3 (6/6, 100%), and most of the significant correlations among CpGs within region 2 (11/13, 85%) were positive. Moreover, there was a tendency for CpGs in regions 2 and 3 to be methylated in opposite directions: most of the significant correlations (17/22, 77%) were negative. In contrast, regions 1 and 3 tended to be methylated in the same direction, with all significant correlations (12/12, 100%) positive. 10 
Association between methylation and genotype
After correcting for multiple testing, there was evidence for an association between APOE carrier-status and DNA methylation at five CpGs in the fully-adjusted models: cg14123992 (η 2 =0.003, p=3.9x10 -4 ), cg04406254 (η 2 =0.004 p=4.0x10 -6 ), cg06750524 (η 2 =0.022, p=8.6x10 - 16 ), cg16471933 (η 2 = 0.014, p=2.4x10 -16 ), and cg21879725 (η 2 =0.003, p=1.3x10 -4 ) (Figure 2, Supp. Table 2 ). Post-hoc testing between the APOE groups showed that at all five CpGs the associations were due to higher methylation levels in ε4 carriers compared to ε3 carriers.
Age-dependent drift in DNA-methylation
In the basic-adjusted model, 7/13 CpGs showed an association with age after correction for multiple testing (R 2 range: 4.0x10 -5 -0.03; Supp. Table 3 ). Three CpGs remained significant after correction for multiple testing in the fully-adjusted model (Figure 3 , Supp. Table 3 ). Most
CpGs within a region exhibited the same direction of change with respect to aging. CpGs in the generally hypomethylated region 2 tended to have greater methylation with older age,
whereas CpGs in the generally hypermethylated regions 1 and 3 tended to have lower methylation with older age. None of the CpGs in our analyses were in a list of age-related variable methylated positions (aVMPs; [36] ). However, the Breusch-Pagan test for heteroscedasticity indicated non-random variation in the residuals by age for all CpGs in both the basic-and the fully-adjusted models (Supp. Table 4 ).
APOE methylation and cognitive function
We observed no association between general cognitive ability and DNA methylation in the fully-adjusted regression models after correction for multiple testing (Supp. Table 5 ). There 11 were associations between the individual cognitive tests and DNA methylation levels in the basic-but not fully-adjusted regression models (Supp. Table 6 ).
APOE methylation and the risk of AD
To determine whether carrier-status was associated with AD-class (0: absence of the disorder, 1: presence of the disorder), a logistic regression was run, with AD-class as the outcome variable and carrier-status as the predictor. We observed no associations between DNA methylation levels and AD-risk in the basic-or fully-adjusted models after correcting for multiple testing (Supp. . The ε4-allele was significantly associated with the high-risk ADclass both in the basic-(OR=1.70, p=3.2x10 -11 ) and fully-adjusted models (OR=1.77, p=1.2x10 -7 ).
APOE methylation and the risk of CVD
We observed no association between APOE methylation and the risk measure of CVD, nor was there an association between APOE genotype and the risk measure of CVD (Supp . Table   8 ). However, APOE genotype was linked to the total-to-HDL cholesterol ratio in the fullyadjusted model (χ 2 =68.5, p=1.3x10 -15 ). Specifically, both the ε2-and ε4-carriers differed in the ratio of total-to-HDL cholesterol compared to ε3-carriers in the fully-adjusted model (ε2: estimate=-0.22, SE=0.048, p=6.4x10 -6 ; ε4: estimate=0.21, SE=0.036, p=1.2x10 -8 ). The ratio of total-to-HDL cholesterol was significantly associated with methylation levels after 12 correcting for multiple testing at three CpGs in the fully-adjusted models: cg08955609, cg18768621, and cg16471933 (Supp. Table 9 ). Due to the strong association between APOE genotype and cholesterol levels, the fully-adjusted model was rerun with APOE-genotype as covariate; cg08955609 (estimate=-0.065, SE=0.019, p=6.7x10 -4 ) and cg18768621 (estimate=-0.059, SE=0.017, p=4.3x10 -4 ) remained statistically significant (Figure 4, Supp. Table 9 ). The validity of CVD-risk as a risk measure for CVD was confirmed by running a linear regression model, with self-reported CVD as an outcome measure and CVD-risk as a predictor variable, with covariates as in the fully-adjusted model above (estimate=0.02, error=0.0032, p=2.1x10 -11 ).
Discussion
Correlations between CpGs and age-drift in methylation
In this study, we used DNA methylation-and phenotypic data from a large cohort, Generation Scotland, to explore methylation in the APOE gene and its association with risk factors for AD, CVD, and blood cholesterol.
We observed correlations among CpGs which had been reported before [19] . Compared with Liu et al. [19] , the correlations observed in our study were stronger and more of them were negative. In contrast to the findings of Karlsson et al. [15] , the methylation levels of five CpGs correlated with carrier-status for the different APOE alleles. This difference may be due to the increased power of our study over that of Karlsson et al. [15] .
We replicated a finding by Ma et al. [22] of age-drift in methylation in the APOE gene: 3/13
CpGs showed age-dependent changes. In each hypermethylated CpG, methylation levels 13 tended to decrease with age, while in each hypomethylated CpG, methylation levels tended to increase with age. All CpGs exhibited heteroscedasticity for the change in methylation as a function of age, demonstrating that the drift could be due to increases in methylomic variability with increasing age.
Relationship between APOE methylation, AD and cognition
Neither cognition, nor family history of AD were associated with APOE methylation. This might be due to a lack of appreciable changes in APOE methylation before the onset of symptoms of AD. Most previous studies that linked differential APOE methylation with AD were conducted on tissue from patients that had either been screened positive for cognitive dysfunction [15] , or diagnosed with AD [14, 16, 17] ; only one study [19] evaluated the relationship between DNA methylation and cognition in healthy participants. The epigenetic changes in APOE accompanying AD-related cognitive decline could result from the pathophysiology of the disorder or from adaptive responses of the organism as a result of AD, neither of which may be present at appreciable levels in the population studied here. Another consideration concerns the tissue used. Foraker et al. [14] used post-mortem brain-tissue, Karlsson et al. [15] and Liu et al. [19] used blood, while Shao et al. [16] and Wang et al. [17] used both. In fact, the latter were not able to replicate their findings from brain-tissue in blood. Blood represents an attractive medium for identifying biomarkers for disease. Indeed, it has been reported that patients with AD and healthy controls can be distinguished based on gene-expression patterns in blood [37] . However, the APOE gene is differently expressed between brain tissue and blood [16, 17] and APOE CpGs exhibit relatively modest correlations between blood-and brain methylation [33, 34, 35] . Thus, blood-methylation may exhibit AD- 14 associated changes that are distinct from methylation changes in the brain or they might appear later in the course of the disorder. Finally, while some studies have reported ADassociated changes in APOE methylation as described above, little research has been done on the topic and few -if any -replication studies have been performed to validate the effects.
Moreover, some prominent studies that investigated associations between DNA methylation and AD across the entire genome did not report APOE to be altered in the disorder [13, 38] .
Relationship between APOE methylation and blood cholesterol
We did not replicate the finding [24] of an association between APOE methylation and CVD;
our results are in line with reports by Karlsson et al. [15] and Sharma et al. [39] . However, we did find a negative association between APOE methylation and the ratio of the total to HDLcholesterol at cg08955609 and cg18768621; a finding that -to our knowledge -had not been reported before. Our measurements of cholesterol provide only levels of total blood cholesterol and of HDL cholesterol. Because of this -especially considering the opposite correlation of APOE genotype with the concentrations of LDL and VLDL, respectively [40] -it is not possible to assess the relationship between methylation and the individual components of blood cholesterol.
Limitations and future directions
The results of the present study offer additional insight into the epigenetics of the APOE gene and its association with relevant phenotypes. The main strength of the study is the large sample size from a relatively representative sample of the Scottish population. Nevertheless, 15 we recognize several limitations. Firstly, the measures of risk for AD and CVD were inferred from information on participants' relatives. The rough approximation of risk underestimates the importance of environmental factors. Moreover, different participants in our cohort have different numbers of relatives. Secondly, the study is limited to (a subset of) the methylome;
other important epigenetic mechanisms that are currently less accessible to analysis at scale might also play important roles in the studied interactions. Thirdly, our study is based on methylation data from the blood, which for most CpGs correspond to methylation patterns in the brain. This might preclude the identification of potential epigenetic changes prior to disease onset and allows only limited insight into underlying biological processes. However, due to the multitude of peripheral biological processes associated with AD, blood may be a legitimate tissue for DNA methylation studies. Finally, this study adopts a candidate gene approach; while APOE is a biologically plausible candidate for implications in AD and CVD, genome-wide approaches may inform on the relative importance of APOE.
In conclusion, we showed that CpGs in the APOE gene exhibit correlations within-and between distinct regions of the gene and that the methylation levels at some CpGs of the APOE gene correlate with the APOE genotype. Furthermore, we found an association between methylation level at cg8955609 and cg18768621, and blood cholesterol. We did not find differences in the levels of APOE methylation between individuals at low risk and individuals at high risk of developing either AD or CVD. Future work might explore longitudinal changes in methylation as it relates to adverse health outcomes to circumvent the problems of the present study and improve our understanding of the exact timing of epigenetic changes in AD and CVD. ε4-carrier 1526 27.5 * The median is given when appropriate (denoted with *). † The interquartile range is given when appropriate (denoted with *). 19 Figure 2 : Boxplots (left) and density plots (right) for differences in methylation levels between groups with different carrier-status. The statistically significant differences between groups after adjusting for multiple comparisons (p < 0.0035) are denoted with asterisks. Depicted are only CpGs for which the fully-adjusted mixed linear models and post-hoc tests between carriers were significant after adjusting for multiple testing. 
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